WallStSmart

Dell Technologies Inc (DELL)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Dell Technologies Inc generates 81% more annual revenue ($113.54B vs $62.58B). PFE leads profitability with a 12.4% profit margin vs 5.2%. DELL appears more attractively valued with a PEG of 0.65. DELL earns a higher WallStSmart Score of 78/100 (B+).

DELL

Strong Buy

78

out of 100

Grade: B+

Growth: 8.0Profit: 6.5Value: 10.0Quality: 5.8
Piotroski: 5/9

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DELLUndervalued (+69.5%)

Margin of Safety

+69.5%

Fair Value

$406.69

Current Price

$157.67

$249.02 discount

UndervaluedFair: $406.69Overvalued
PFESignificantly Overvalued (-191.6%)

Margin of Safety

-191.6%

Fair Value

$9.25

Current Price

$26.97

$17.72 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DELL6 strengths · Avg: 9.5/10
Return on EquityProfitability
44.3%10/10

Every $100 of equity generates 44 in profit

Revenue GrowthGrowth
39.5%10/10

Revenue surging 39.5% year-over-year

EPS GrowthGrowth
57.3%10/10

Earnings expanding 57.3% YoY

Debt/EquityHealth
-11.9210/10

Conservative balance sheet, low leverage

Market CapQuality
$104.49B9/10

Large-cap with strong market position

PEG RatioValuation
0.658/10

Growing faster than its price suggests

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.41B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

DELL1 concerns · Avg: 3.0/10
Profit MarginProfitability
5.2%3/10

5.2% margin — thin

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-120.0%2/10

Revenue declined 120.0%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : DELL

The strongest argument for DELL centers on Return on Equity, Revenue Growth, EPS Growth. Revenue growth of 39.5% demonstrates continued momentum. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : DELL

The primary concerns for DELL are Profit Margin.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

DELL profiles as a hypergrowth stock while PFE is a declining play — different risk/reward profiles.

DELL carries more volatility with a beta of 1.04 — expect wider price swings.

DELL is growing revenue faster at 39.5% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

DELL scores higher overall (78/100 vs 49/100) and 39.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dell Technologies Inc

TECHNOLOGY · COMPUTER HARDWARE · USA

Dell Technologies Inc. designs, develops, manufactures, markets, sells and supports information technology solutions, products and services worldwide. The company is headquartered in Round Rock, Texas.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?